The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica said it plans to launch the trial later in 2026
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
